Literature DB >> 11138723

The parkinsonian models: invertebrates to mammals.

Y Kitamura1, S Shimohama, A Akaike, T Taniguchi.   

Abstract

In contrast to Alzheimer's disease, effective therapeutic options are available for Parkinson's disease. Therapy of dopamine replacement such as levodopa improves the symptoms of this disease, but does not inhibit neurodegeneration in the substantia nigra. Numerous studies have suggested that endogenous and environmental neurotoxins, and oxidative stress may participate in this disease, but the detailed mechanisms are still unclear. Recent genetic studies in familial Parkinson's disease and parkinsonism show several gene mutations. This new information regarding pathogenesis offers novel prospects for therapy. To develop novel neuroprotective drugs, it is necessary to have a model for each type of parkinsonism. This review summarizes current findings regarding parkinsonian models in vertebrates and invertebrates and discusses their value.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11138723     DOI: 10.1254/jjp.84.237

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  9 in total

Review 1.  Role of reactive oxygen species in the neurotoxicity of environmental agents implicated in Parkinson's disease.

Authors:  Derek A Drechsel; Manisha Patel
Journal:  Free Radic Biol Med       Date:  2008-03-04       Impact factor: 7.376

Review 2.  Targeting the chameleon: a focused look at α-synuclein and its roles in neurodegeneration.

Authors:  Blanca A Silva; Leonid Breydo; Vladimir N Uversky
Journal:  Mol Neurobiol       Date:  2012-09-01       Impact factor: 5.590

Review 3.  Metallothionein-mediated neuroprotection in genetically engineered mouse models of Parkinson's disease.

Authors:  Manuchair Ebadi; Holly Brown-Borg; Hesham El Refaey; Brij B Singh; Scott Garrett; Shaik Shavali; Sushil K Sharma
Journal:  Brain Res Mol Brain Res       Date:  2005-03-24

Review 4.  Melanin affinity and its possible role in neurodegeneration.

Authors:  Oskar Karlsson; Nils Gunnar Lindquist
Journal:  J Neural Transm (Vienna)       Date:  2013-07-03       Impact factor: 3.575

5.  Neuroprotective mechanisms of antiparkinsonian dopamine D2-receptor subfamily agonists.

Authors:  Yoshihisa Kitamura; Takashi Taniguchi; Shun Shimohama; Akinori Akaike; Yasuyuki Nomura
Journal:  Neurochem Res       Date:  2003-07       Impact factor: 3.996

Review 6.  Stroke, dementia, and drug delivery.

Authors:  G A Ford; C A Bryant; A A Mangoni; S H D Jackson
Journal:  Br J Clin Pharmacol       Date:  2004-01       Impact factor: 4.335

7.  Activation of NF-kappaB p65/c-Rel dimer is associated with neuroprotection elicited by mGlu5 receptor agonists against MPP(+) toxicity in SK-N-SH cells.

Authors:  I Sarnico; F Boroni; M Benarese; S Sigala; A Lanzillotta; L Battistin; P Spano; M Pizzi
Journal:  J Neural Transm (Vienna)       Date:  2007-12-19       Impact factor: 3.575

Review 8.  Environmental estrogen-like chemicals and hydroxyl radicals induced by MPTP in the striatum: a review.

Authors:  Toshia Obata
Journal:  Neurochem Res       Date:  2002-05       Impact factor: 3.996

9.  An exploratory evaluation of tyrosine hydroxylase inhibition in planaria as a model for parkinsonism.

Authors:  David Prokai; Thinh Nguyen; Kurt Kamrowski; Ashwin Chandra; Tatjana Talamantes; Lewis R Baxter; Laszlo Prokai
Journal:  Int J Mol Sci       Date:  2013-11-26       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.